Clinical and genetic characteristics of BAP1-mutated non-uveal and uveal melanoma
Johanna Matull(German Cancer Research Center), Klaus Griewank(Düsseldorf University Hospital), Patrick Terheyden(University Hospital Schleswig-Holstein), Jochen Utikal(German Cancer Research Center), Rudolf Herbst(Helios Klinikum Erfurt), Inga Möller(Düsseldorf University Hospital), Claudia Pföhler(Saarland University), Dirk Schadendorf(National Center for Tumor Diseases), Jan‐Malte Placke(Düsseldorf University Hospital), Georg Lodde(Essen University Hospital), Annette Paschen(University of Duisburg-Essen), Carl Maximilian Thielmann(German Cancer Research Center), Julia Welzel(University Hospital Augsburg), Elisabeth Livingstone(German Cancer Research Center), Antje Sucker(German Cancer Research Center), Selma Ugurel(Klinikum Bielefeld), Lisa Zimmer(The University of Sydney), Anne Zaremba(National Center for Tumor Diseases), Julia Kretz(German Cancer Research Center), Alexander Kreuter(HELIOS St. Elisabeth Klinik Oberhausen), Eva Hadaschik(West German Heart and Vascular Center Essen)
Cited by 11
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade
|Science|2016|3.1k
Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib
|New England Journal of Medicine|2014|2.7k